Immuneering Corporation

Healthcare

NASDAQ:IMRX · NASDAQ Global Market

Market Cap $160.09M Beta 0.38 P/E (TTM) -3.6

$4.41 -0.14%

-$0.01 today

52W Low $2.29High $10.08

Vol 1.00M · Avg 1.38M

EPS (TTM) -$1.24Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+80.74%

Period High

$9.26

Period Low

$2.44

Latest

$4.41

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Assembly Biosciences, Inc.

NASDAQ:ASMB

$388.47M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

$293.92M

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

$278.94M

Entrada Therapeutics, Inc.

NASDAQ:TRDA

$267.28M

Foghorn Therapeutics Inc.

NASDAQ:FHTX

$243.08M

Zura Bio Limited

NASDAQ:ZURA

$241.50M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

$212.32M

Humacyte, Inc.

NASDAQ:HUMA

$157.32M

Pyxis Oncology, Inc.

NASDAQ:PYXS

$127.03M

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

$117.89M

What is the latest IMRX filing?

The latest filing shown is 4 dated Jun 16, 2026.

How many recent filings does IMRX have?

Intrinsic Alpha currently shows 20 recent filings for IMRX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.